ontario regulation 17/17

made under the

Optometry Act, 1991

Made: November 9, 2016
Approved: February 2, 2017
Filed: February 6, 2017
Published on e-Laws: February 6, 2017
Printed in The Ontario Gazette: February 25, 2017

Amending O. Reg. 112/11

(DESIGNATED DRUGS AND STANDARDS OF PRACTICE)

1. Section 2 of Ontario Regulation 112/11 is revoked and the following substituted:

Limitations

2. Where a limitation or a route of administration is indicated with respect to a drug listed in Schedule 1, either in a sub-category heading or with respect to that particular drug, a member shall only prescribe the drug in compliance with the limitation and in accordance with the route of administration specified.

2. (1) Schedule 1 to the Regulation is amended by adding the following drug under the sub-category heading “Corticosteroids (topical)”:

difluprednate

(2) Schedule 1 to the Regulation is amended by adding the following sub-category headings and drugs under the category heading “ANTI-INFLAMMATORY AGENTS”:

Corticosteroids (topical) – for the purpose of treating conditions of the eye and adnexa

triamcinolone

Immunomodulators (topical)

cyclosporine

(3) Schedule 1 to the Regulation is amended by adding the following drug under the sub-category heading “Nonsteroidal anti-inflammatory agents (topical)”:

bromfenac

(4) Schedule 1 to the Regulation is amended by adding the following drug under the sub-category heading “Mydriatics (topical)”:

tropicamide

(5) Schedule 1 to the Regulation is amended by adding the following drugs under the sub-category heading “Antiallergic agents (topical)”:

bepotastine

tacrolimus – for the purpose of treating conditions of the eye and adnexa and for a duration not exceeding 42 days

(6) Schedule 1 to the Regulation is amended by adding the following drug under the sub-category heading “Prostaglandin analogs (topical)”:

tafluprost

(7) Schedule 1 to the Regulation is amended by adding the following drug under the sub-category heading “Carbonic anhydrase inhibitors/β-adrenergic blocking agents (topical)”:

brinzolamide/timolol

(8) Schedule 1 to the Regulation is amended by adding the following sub-category heading and drug under the category heading “ANTIGLAUCOMA AGENTS”:

Carbonic anhydrase inhibitors (oral) – to lower intraocular pressure only and a member shall immediately refer the patient to a physician or to a hospital

acetazolamide

(9) Schedule 1 to the Regulation is amended by adding the following category:

SECRETAGOGUES

Secretagogues (oral) – for Sjögren’s syndrome only and only in collaboration with a physician with whom the member has established a co-management model of care

pilocarpine

Commencement

3. This Regulation comes into force on the day it is filed.

Made by:

Council of the College of Optometrists of Ontario:

Dr. Thomas-A. Noël

President

Paula Garshowitz

Registrar

Date made: November 9, 2016